nateglinide
Sign in to saveAlso known as DJN608, AY-4166, SDZ-DJN-608, trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine, AY4166, A-4166, AY 4166, A 4166
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.
Research
622 papers- Nateglinide.2006
- Nateglinide.2012
- Nateglinide: A comprehensive profile.Profiles of drug substances, excipients, and related methodology · 2025
- Nateglinide.Drugs · 2000
- Nateglinide.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001
via PubMed
~3 min read
Encyclopedic overview
7 sectionsContents
- Pharmacology
- Contraindications
- Comparisons with other drugs for type 2 diabetes
- Dosage
- See also
- References
- External links
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 462258838 | IUPAC_name = (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid | image = Nateglinide.svg | image_class = skin-invert-image
| tradename = Starlix | Drugs.com = | MedlinePlus = a699057 | licence_EU = yes | licence_US = Nateglinide | pregnancy_category = | legal_UK = POM | legal_US = Rx-only | legal_status = | routes_of_administration = Oral
Excerpted from Wikipedia’s “nateglinide” article, available under the CC BY-SA 4.0 licence.
Available in 17 languages
- Español
- Français
- 日本語
- Português
- Italiano
- العربية
- Bahasa Indonesia
- Nederlands
- Odia
- Romanian
- Serbian
- Serbian (Latin)
- Telugu
- Tiếng Việt
- Welsh
- فارسی
via Wikidata sitelinks · CC0